

Daftar Pustaka

1. WHO. WHO reveals leading causes of death and disability worldwide: 2000-2019. Published online 2020. <https://www.who.int/news/item/09-12-2020-who-reveals-leading-causes-of-death-and-disability-worldwide-2000-2019>
2. Cesare MD, Bixby H, Gaziano T, et al. World Heart Report 2023: Confronting the World's Number One Killer. *World Heart Fed*. Published online 2023;1-52. <https://world-heart-federation.org/wp-content/uploads/World-Heart-Report-2023.pdf>
3. Kementrian Kesehatan Republik Indonesia. Cegah Penyakit Jantung dengan Menerapkan Perilaku CERDIK dan PATUH. Published online 2023. <https://sehatnegeriku.kemkes.go.id/baca/rilismedia/20230925/4943963/cegah-penyakit-jantung-dengan-menerapkanperilaku-cerdik-dan-patuh/>
4. World Health Organization. Cardiovascular diseases (CVDs). 2021. [https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-\(cvds\)](https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds))
5. Hasanah, Zulkarnain E, Arifianto H, et al. Pedoman Tatalaksana Gagal Jantung. *Perhimpun Dr Spes Kardiovask Indones*. 2023;3:1-113.
6. Bozkurt B, Coats AJS, Tsutsui H, et al. Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition o. *Eur J Heart Fail*. 2021;23(3):352-380. doi:10.1002/ejhf.2115
7. Shams P, Goyal A, Makaryus AN. *Left Ventricular Ejection Fraction.*; 2025. <http://www.ncbi.nlm.nih.gov/pubmed/38099892>
8. Azevedo PS, Polegato BF, Minicucci MF, Paiva SAR, Zornoff LAM. Cardiac Remodeling: Concepts, Clinical Impact, Pathophysiological Mechanisms and Pharmacologic Treatment. *Arq Bras Cardiol*. Published online 2016. doi:10.5935/abc.20160005

9. Sari RN, Habib F. Hubungan Nilai Fraksi Ejeksi Ventrikel Kiri pada Pasien Gagal Jantung dengan Tingkat Gejala Depresi yang Diukur dengan The Beck Depression Inventory II (BDI-II). *J PANDU HUSADA*. 2021;2(1):46. doi:10.30596/jph.v2i1.5377
10. Ommen SR, Hodge DO, Rodeheffer RJ, McGregor CGA, Thomson SP, Gibbons RJ. Predictive Power of the Relative Lymphocyte Concentration in Patients With Advanced Heart Failure. *Circulation*. 1998;97(1):19-22. doi:10.1161/01.CIR.97.1.19
11. Silva N, Bettencourt P, Guimarães JT. The lymphocyte-to-monocyte ratio: An added value for death prediction in heart failure. *Nutr Metab Cardiovasc Dis*. 2015;25(11):1033-1040. doi:10.1016/j.numecd.2015.07.004
12. Yaqin MA, Ristyaning P, Sangging A, et al. Hubungan Rasio Limfosit Monosit (RLM) dengan Fraksi Ejeksi Ventrikel Kiri pada Pasien Gagal Jantung Relationship Between Monocyte Lymphocyte Ratio (RML) and Left Ventricular Ejection Fraction on Heart Failure Patients. 14(September 2024):1743-1748.
13. Charach G, Grosskopf I, Roth A, et al. Usefulness of Total Lymphocyte Count as Predictor of Outcome in Patients With Chronic Heart Failure. *Am J Cardiol*. 2011;107(9):1353-1356. doi:10.1016/j.amjcard.2010.12.049
14. Mann DL. Innate Immunity and the Failing Heart. *Circ Res*. 2015;116(7):1254-1268. doi:10.1161/CIRCRESAHA.116.302317
15. Getawa S, Bayleyegn B. Platelet, Neutrophil and Lymphocyte Quantitative Abnormalities in Patients with Heart Failure: A Retrospective Study. *Vasc Health Risk Manag*. 2023;19:69-78. doi:10.2147/VHRM.S394765
16. Polat N, Yıldız A, Bilik MZ, et al. The importance of hematologic indices in the risk stratification of patients with acute decompensated systolic heart failure. *Turk Kardiyol Dern Ars*. 2015;43(2):157-165. doi:10.5543/tkda.2015.76281

17. Zhu Z, Zhou S. Leukocyte count and the risk of adverse outcomes in patients with HFpEF. *BMC Cardiovasc Disord.* 2021;21(1):333. doi:10.1186/s12872-021-02142-y
18. Lawson CA, Zaccardi F, Squire I, et al. Risk Factors for Heart Failure. *Circ Hear Fail.* 2020;13(2). doi:10.1161/CIRCHEARTFAILURE.119.006472
19. Mahmood SS, Wang TJ. The Epidemiology of Congestive Heart Failure: Contributions from the Framingham Heart Study. *Glob Heart.* 2013;8(1):77. doi:10.1016/j.gheart.2012.12.006
20. Golla MSG, Hajouli S, Ludhwani D. *Heart Failure and Ejection Fraction.*; 2025. <http://www.ncbi.nlm.nih.gov/pubmed/37011077>
21. Shams P, Malik A, Chhabra L. *Heart Failure (Congestive Heart Failure).*; 2025. <http://www.ncbi.nlm.nih.gov/pubmed/35363499>
22. Sherwood L. *Human Physiology: From Cells to Systems.* 9th ed. Cengage Learning.; 2016.
23. Devi A, Thielemans L, Ladikou EE, Nandra TK, Chevassut T. Lymphocytosis and chronic lymphocytic leukaemia: investigation and management. *Clin Med (Northfield Il).* 2022;22(3):225-229. doi:10.7861/clinmed.2022-0150
24. Mims MP. Lymphocytosis, Lymphocytopenia, Hypergammaglobulinemia, and Hypogammaglobulinemia. In: *Hematology.* Elsevier; 2018:682-690. doi:10.1016/B978-0-323-35762-3.00049-4
25. Bazgir F, Nau J, Nakhaei-Rad S, et al. The Microenvironment of the Pathogenesis of Cardiac Hypertrophy. *Cells.* 2023;12(13):1780. doi:10.3390/cells12131780
26. Blum A. Role of Lymphocytes in Heart Disease. *Circulation.* 1998;98(15). doi:10.1161/circ.98.15.1587/c
27. Lv J, Xu H, Ye Y, et al. Meta-Analysis Global Group in Chronic Heart

- Failure score for the prediction of mortality in valvular heart disease. *ESC Hear Fail*. 2024;11(1):349-365. doi:10.1002/ehf2.14586
28. Tromp J, Paniagua SMA, Lau ES, et al. Age dependent associations of risk factors with heart failure: pooled population based cohort study. *BMJ*. Published online March 23, 2021:n461. doi:10.1136/bmj.n461
 29. Wiratama FF, Alvina. HUBUNGAN USIA DAN JENIS KELAMIN DENGAN KUALITAS HIDUP PASIEN GAGAL JANTUNG. *J Akta Trimedika*. 2025;2(2):685-694. <https://e-journal.trisakti.ac.id/index.php/aktatrimedika/article/view/22319>
 30. Putri AD, Rizkifani S, Nurbaeti SN. Analisis Hubungan Perawatan Diri dengan Kualitas Hidup pada Pasien Gagal Jantung Kongestif. *Media Karya Kesehat*. 2023;6(2):267-283.
 31. Rezalina S, Meilando R, Faizal M. Pengaruh Mobilisasi Progresif Level 1 terhadap Status Hemodinamik pada Pasien. 2024;1(1):1-9.
 32. Priandani, Hendra, Kusumajaya, Permatasari. I. Faktor-Faktor Yang Berhubungan Dengan Kejadian Congestive Heart Failure (Chf) Pasien. *J Penelit Perawat Prof*. 2022;4(November):1377-1386.
 33. Walli-Attaei M, Joseph P, Johansson I, et al. Characteristics, management, and outcomes in women and men with congestive heart failure in 40 countries at different economic levels: an analysis from the Global Congestive Heart Failure (G-CHF) registry. *Lancet Glob Heal*. 2024;12(3):e396-e405. doi:10.1016/S2214-109X(23)00557-0
 34. Siswanto BB, Radi B, Radi B, et al. Heart Failure in NCVJ Jakarta and 5 hospitals in Indonesia. *Glob Heart*. 2010;5(1):35. doi:10.1016/j.cvdpc.2010.03.005
 35. Iorga A, Cunningham CM, Moazeni S, Ruffenach G, Umar S, Eghbali M. The protective role of estrogen and estrogen receptors in cardiovascular disease and the controversial use of estrogen therapy. *Biol Sex Differ*.

2017;8(1):33. doi:10.1186/s13293-017-0152-8

36. Gao Z, Chen Z, Sun A, Deng X. Gender differences in cardiovascular disease. *Med Nov Technol Devices*. 2019;4:100025. doi:10.1016/j.medntd.2019.100025
37. Wijesinghe S, Dikou ML, Kasouridis I, et al. Sex Differences in Heart Failure: A Step Forward. *Interv Cardiol Rev Res Resour*. 2025;20. doi:10.15420/icr.2024.30
38. Regitz-Zagrosek V, Oertelt-Prigione S, Seeland U, Hetzer R. Sex and Gender Differences in Myocardial Hypertrophy and Heart Failure. *Circ J*. 2010;74(7):1265-1273. doi:10.1253/circj.CJ-10-0196
39. Abdissa SG. Predictors of incident heart failure in a cohort of patients with ischemic heart disease. *Pan Afr Med J*. 2020;35. doi:10.11604/pamj.2020.35.45.18257
40. Rosano GM, Vitale C, Seferovic P. Heart Failure in Patients with Diabetes Mellitus. *Card Fail Rev*. 2017;03(01):52. doi:10.15420/cfr.2016:20:2
41. Arhlade F, Asadi A, Raboukhi S, Habbal R. 0097 : Influence of dyslipidemia on clinical characteristics in heart failure patients. Series of 583 cases. *Arch Cardiovasc Dis Suppl*. 2015;7(2):178. doi:10.1016/S1878-6480(15)30130-0
42. Lee SH, Lee KN, Youn JC, Kim HS, Han K, Kim MK. Different Associations between Lipid Levels and Risk for Heart Failure according to Diabetes Progression. *Diabetes Metab J*. 2025;49(1):105-116. doi:10.4093/dmj.2024.0066
43. Ebong IA, Goff DC, Rodriguez CJ, Chen H, Sibley CT, Bertoni AG. Association of Lipids With Incident Heart Failure Among Adults With and Without Diabetes Mellitus. *Circ Hear Fail*. 2013;6(3):371-378. doi:10.1161/CIRCHEARTFAILURE.112.000093
44. Velagaleti RS, Massaro J, Vasan RS, Robins SJ, Kannel WB, Levy D.

- Relations of Lipid Concentrations to Heart Failure Incidence. *Circulation*. 2009;120(23):2345-2351. doi:10.1161/CIRCULATIONAHA.109.830984
45. Celentano A, Crivaro M, Roman MJ, et al. Left ventricular geometry and arterial function in hypercholesterolemia. *Nutr Metab Cardiovasc Dis*. 2001;11(5):312-319. <http://www.ncbi.nlm.nih.gov/pubmed/11887428>
 46. Hermawan IKH, Kawilarang KC, Hartono F. Clinical Characteristics and Profile of Heart Failure Patients at dr. Ramelan Navy Hospital in 2020. *Cardiovasc Cardiometabolic J*. 2022;3(1):9-14. doi:10.20473/ccj.v3i1.2022.9-14
 47. Gallo G, Savoia C. Hypertension and Heart Failure: From Pathophysiology to Treatment. *Int J Mol Sci*. 2024;25(12):6661. doi:10.3390/ijms25126661
 48. Slivnick J, Lampert BC. Hypertension and Heart Failure. *Heart Fail Clin*. 2019;15(4):531-541. doi:10.1016/j.hfc.2019.06.007
 49. Izumi C, Matsuyama R, Yamabe K, et al. In-Hospital Outcomes of Heart Failure Patients with Valvular Heart Disease: Insights from Real-World Claims Data. *Clin Outcomes Res*. 2023;Volume 15:349-360. doi:10.2147/CEOR.S405079
 50. Cowie M. Incidence and aetiology of heart failure; a population-based study. *Eur Heart J*. 1999;20(6):421-428. doi:10.1053/euhj.1998.1280
 51. Gheorghiade M, Bonow RO. Chronic Heart Failure in the United States. *Circulation*. 1998;97(3):282-289. doi:10.1161/01.CIR.97.3.282
 52. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart failure. *JAMA*. 275(20):1557-1562. <http://www.ncbi.nlm.nih.gov/pubmed/8622246>
 53. Vedin O, Lam CSP, Koh AS, et al. Significance of Ischemic Heart Disease in Patients With Heart Failure and Preserved, Midrange, and Reduced Ejection Fraction. *Circ Hear Fail*. 2017;10(6).

doi:10.1161/CIRCHEARTFAILURE.117.003875

54. Albakri A. Ischemic heart failure: A review of clinical status and meta-analysis of diagnosis and clinical management methods. *Clin Med Investig.* 2018;3(4). doi:10.15761/CMI.1000171
55. Severino P, D'Amato A, Pucci M, et al. Ischemic Heart Disease and Heart Failure: Role of Coronary Ion Channels. *Int J Mol Sci.* 2020;21(9):3167. doi:10.3390/ijms21093167
56. Remme WJ. Overview of the relationship between ischemia and congestive heart failure. *Clin Cardiol.* 2000;23(S4):IV-4-IV-8. doi:10.1002/clc.4960230703
57. Feng J, Zhang Y, Zhang J. Epidemiology and Burden of Heart Failure in Asia. *JACC Asia.* 2024;4(4):249-264. doi:10.1016/j.jacasi.2024.01.013
58. Ide T, Kaku H, Matsushima S, et al. Clinical Characteristics and Outcomes of Hospitalized Patients With Heart Failure From the Large-Scale Japanese Registry Of Acute Decompensated Heart Failure (JROADHF). *Circ J.* 2021;85(9):CJ-20-0947. doi:10.1253/circj.CJ-20-0947
59. Hamaguchi S, Kinugawa S, Tsuchihashi-Makaya M, et al. Characteristics, management, and outcomes for patients during hospitalization due to worsening heart failure—A report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). *J Cardiol.* 2013;62(2):95-101. doi:10.1016/j.jjcc.2013.03.009
60. Sato N, Kajimoto K, Keida T, et al. Clinical Features and Outcome in Hospitalized Heart Failure in Japan (From the ATTEND Registry). *Circ J.* 2013;77(4):944-951. doi:10.1253/circj.CJ-13-0187
61. Shiraishi Y, Kohsaka S, Sato N, et al. 9-Year Trend in the Management of Acute Heart Failure in Japan: A Report From the National Consortium of Acute Heart Failure Registries. *J Am Heart Assoc.* 2018;7(18). doi:10.1161/JAHA.118.008687

62. Marciniak A, Glover K, Sharma R. Cohort profile: prevalence of valvular heart disease in community patients with suspected heart failure in UK. *BMJ Open*. 2017;7(1):e012240. doi:10.1136/bmjopen-2016-012240
63. Maganti K, Rigolin VH, Sarano ME, Bonow RO. Valvular Heart Disease: Diagnosis and Management. *Mayo Clin Proc*. 2010;85(5):483-500. doi:10.4065/mcp.2009.0706
64. Shah SN, Sharma S. *Mitral Stenosis*.; 2025. <http://www.ncbi.nlm.nih.gov/pubmed/30229690>
65. Vaduganathan M, Ambrosy AP, Greene SJ, et al. Predictive Value of Low Relative Lymphocyte Count in Patients Hospitalized for Heart Failure With Reduced Ejection Fraction. *Circ Hear Fail*. 2012;5(6):750-758. doi:10.1161/CIRCHEARTFAILURE.112.970525
66. Acanfora D, Gheorghiade M, Trojano L, et al. Relative lymphocyte count: A prognostic indicator of mortality in elderly patients with congestive heart failure. *Am Heart J*. 2001;142(1):167-173. doi:10.1067/mhj.2001.115792
67. Rudiger A, Burckhardt OA, Harpes P, Müller SA, Follath F. The relative lymphocyte count on hospital admission is a risk factor for long-term mortality in patients with acute heart failure. *Am J Emerg Med*. 2006;24(4):451-454. doi:10.1016/j.ajem.2005.10.010
68. Lehtonen L, Eskola J, Vainio O, Lehtonen A. Changes in Lymphocyte Subsets and Immune Competence in Very Advanced Age. *J Gerontol*. 1990;45(3):M108-M112. doi:10.1093/geronj/45.3.M108
69. Cooper HA, Exner D V, Waclawiw MA, Domanski MJ. White blood cell count and mortality in patients with ischemic and nonischemic left ventricular systolic dysfunction (an analysis of the studies of left ventricular dysfunction [SOLVD]). *Am J Cardiol*. 1999;84(3):252-257. doi:10.1016/S0002-9149(99)00272-6
70. Christersson M, Gustafsson S, Lampa E, et al. Usefulness of Heart Failure

Categories Based on Left Ventricular Ejection Fraction. *J Am Heart Assoc.* 2024;13(8). doi:10.1161/JAHA.123.032257

71. Dhabhar FS. Stress-induced augmentation of immune function—The role of stress hormones, leukocyte trafficking, and cytokines. *Brain Behav Immun.* 2002;16(6):785-798. doi:10.1016/S0889-1591(02)00036-3
72. Torre-Amione G, Kapadia S, Lee J, et al. Tumor Necrosis Factor- α and Tumor Necrosis Factor Receptors in the Failing Human Heart. *Circulation.* 1996;93(4):704-711. doi:10.1161/01.CIR.93.4.704
73. Westermann D, Lindner D, Kasner M, et al. Cardiac Inflammation Contributes to Changes in the Extracellular Matrix in Patients With Heart Failure and Normal Ejection Fraction. *Circ Hear Fail.* 2011;4(1):44-52. doi:10.1161/CIRCHEARTFAILURE.109.931451
74. Kaur G, Lau E. Sex differences in heart failure with preserved ejection fraction: From traditional risk factors to sex-specific risk factors. *Womens Health (Lond Engl).* 2022;18:17455057221140208. doi:10.1177/17455057221140209
75. Rai A, Narisawa M, Li P, et al. Adaptive immune disorders in hypertension and heart failure: focusing on T-cell subset activation and clinical implications. *J Hypertens.* 2020;38(10):1878-1889. doi:10.1097/HJH.0000000000002456
76. Tang TT, Ding YJ, Liao YH, et al. Defective Circulating CD4⁺CD25⁺Foxp3⁺CD127^{low} Regulatory T-cells in Patients with Chronic Heart Failure. *Cell Physiol Biochem.* 2010;25(4-5):451-458. doi:10.1159/000303050